As NTx commercializes its platform, the company has several collaborations with leading biotechnology companies underway that will serve as the foundation for its global commercial relationships. To support these efforts and meet cGMP regulations, Brancieri will lead projects to advance product development, open new manufacturing facilities, and develop supply strategy, in addition to managing production siting, capital planning, and construction.
Prior to joining NTx, Brancieri served as the Process Engineering Director at global healthcare company, GlaxoSmithKline (GSK). At GSK, Brancieri led the process engineering team within the strategic external development organization, which was responsible for clinical and commercial manufacturing as well as process performance qualification strategy and execution. Before that, Brancieri spent over ten years at global biopharmaceutical company, Bristol Myers Squibb. Brancieri began his tenure there as a Senior Engineer and worked his way up to lead a team of engineers responsible for manufacturing process optimization and technology implementations as Associate Director of Process Engineering.
“It is an honor to be part of the NTx team, delivering solutions that will improve the global accessibility of critical vaccines and other biologic therapeutics,” said Mark Brancieri. “NTx is blazing a new path with its innovative manufacturing technology that will allow companies to rapidly scale-out their production capability and deliver new medicines to patients faster. I’m eager to help enhance NTx’s cGMP capabilities as we make this technology commercially available.”
NTx is a life sciences company enabling novel RNA product development and leading the way in producing high quality extended length mRNA and saRNA transcripts. Its cell-free, continuous-flow process mitigates the typical development challenges by producing extended length material and helps accelerate pre-clinical candidates towards regulatory filings and clinical studies. With the help of the manufacturing initiatives that Brancieri will lead, the NTx platform technologies will rapidly advance medical innovation to benefit patients.
“We are delighted to have Mark join the NTx leadership team and look forward to leveraging his experience in manufacturing process optimization to support NTx as it enters the commercialization phase,” said Dr. Alex Koglin, co-founder and CEO at NTx. “As we work toward meeting cGMP standards, Mark’s knowledge base will be extremely valuable to ensure our manufacturing, supply, and customer service strategies are top notch to meet global demand and improve patient access to therapeutics.”
For more information about NTx and its proprietary platform, please visit: https://www.ntxbio.com.
Nature’s Toolbox, Inc. (NTx) is a life sciences company located in Rio Rancho, New Mexico. The company is commercializing its biomanufacturing systems NTxpress®, NTxscribe® and the bioinformatics platform, DruID, for the discovery of natural products. NTx’s proprietary continuous-flow, fully recombinant, in vitro, cell-free transcription system utilizes hollow fiber bioreactors to support the growing demand for mRNA-based vaccines and therapeutics. NTx’s biomanufacturing processes can easily be scaled to meet fluctuating supply needs so that companies can increase and streamline production as they respond to changing global demands. For more information, please visit: https://www.ntxbio.com.